secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062031
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics Q3 2023 net loss $7.7M; initiates Phase 2a RIVER trial for Haduvio in RCC
--------------------------------------------------------------------------------

- Net loss $7.7M in Q3 2023 vs $8.3M in Q3 2022; cash, equivalents $88.9M.
- Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough; topline data expected H2 2024.
- Plan to initiate Phase 2b dose-ranging trial for chronic cough in IPF in Q4 2023; Phase 1b trial in Q1 2024.
- Open-label extension of PRISM trial in prurigo nodularis showed sustained itch reduction and safety over 52 weeks.
- R&D expenses $6.3M, G&A $2.7M; other income $1.3M due to higher interest income.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017023062031/0000950170-23-062031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017023062031/trvi-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer